The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.

A look back at Medtech Insight’s 10 most-read Start-Up Spotlight stories in 2020 pointed to diverse interest among our readers focusing on orthopedics, innovations in cardiac surgery, portable ultrasound tech and digital tools for tracking vital signs and monitoring patients at home.

The company is developing a novel duodenal mucosal resurfacing technology designed to reverse the metabolic process that causes insulin resistance in people with type 2 diabetes.

The first-in-human study of Fractyl's Revita duodenal mucosal resurfacing system shows significant short-term improvement in hyperglycemia in patients with type 2 diabetes, with few adverse events.